Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer

(2009) Aytekin Guven et al.   ANNALS OF NUCLEAR MEDICINE

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function

(2009) Jaap J. M. Teunissen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

(2008) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY